ByFund Gurus:Pharmaceuticals have been fairly unloved by investors for a number of years. However, as the equity rally continues and prices increase, to me, a number of these companies look incredibly cheap.The healthcare story is one many can relate

* Final-stage studies on olaparib, selumetinib start in H2

* Final-stage studies on olaparib, selumetinib start in H2

With the company's pipeline in turmoil, AstraZeneca looks into the acquisition game.

AstraZeneca is still in free fall. Despite new CEO Pascal Soriot's recovery plan, the U.K. pharmaceutical company will be cliff-jumping for some time yet.

Here's your Cheat Sheet to earnings...

There is a lot about the Anglo-Swedish pharma group not to like, but investors appear willing to give its new chief executive time to succeed

AstraZeneca said profit fell for a fifth-consecutive quarter as patent expiries hit the drug company, while Germany's Bayer was boosted by pharmaceutical-product sales and its agrochemical division.

LONDON, April 25 (Reuters) - Britain's top share index traded flat on Thursday, steadying after recent robust gains, with falls in stocks such as AstraZeneca and Unilever on weak corporate earnings...

* Q1 sales fall 13 pct to $6.39 bln vs consensus $6.51 bln

* Q1 sales fall 13 pct to $6.39 bln vs consensus $6.51 bln

AstraZeneca PLC (AZN.LN) said Thursday profit and sales fell for a fifth-consecutive quarter as the drug giant continues to suffer patent expiries that leave some of its blockbuster products open to competition from generic brands.

LONDON, April 25 (Reuters) - AstraZeneca said on Thursday it had received a subpoena from the U.S. Attorney's Office in Boston, Massachusetts, related to manufacturing standards at its Macclesfield facility in the north of England.

LONDON, April 25 (Reuters) - AstraZeneca said onThursday it had received a subpoena from the U.S. Attorney'sOffice in Boston, Massachusetts, related to manufacturingstandards at its Macclesfield...

LONDON, April 25 (Reuters) - AstraZeneca PLC : * CFO says expects to see U.S. Brilinta growth accelerating at back-end of year

LONDON, April 25 (Reuters) - AstraZeneca PLC : * CFO says expects to see U.S. Brilinta growth accelerating at back-end of year

Loss of patents on some of its best known drugs sends profits at Anglo-Swedish pharmaceuticals maker down more than a third in first quarter

LONDON, April 25 (Reuters) - AstraZeneca PLC : * Shares fall 1.2 percent after Q1 sales miss forecasts

LONDON, April 25 (Reuters) - AstraZeneca's sales fell by a bigger-than-expected 13 percent in the first quarter as patent expiries took a heavy toll, underscoring the turnaround challenge facing Britain's second largest drugmaker.

LONDON, April 25 (Reuters) - AstraZeneca's sales fell by a bigger-than-expected 13 percent in the first quarter as patent expiries took a heavy toll, underscoring the turnaround challenge facing Britain's second largest drugmaker.

LONDON, April 25 (Reuters) - AstraZeneca's sales fell by a bigger-than-expected 13 percent in the first quarter as patent expiries sent revenue from key medicines skidding lower, underscoring the turnaround challenge facing Britain's second biggest d

LONDON, April 25 (Reuters) - AstraZeneca's sales fell by a bigger-than-expected 13 percent in the first quarter as patent expiries sent revenue from key medicines skidding lower, underscoring the turnaround challenge facing Britain's second biggest d

Here's your Cheat Sheet to earnings...

AstraZeneca (AZN) is expected to report poor first quarter earnings on Thursday, April 25, 2013 with analysts expecting a 26% drop in earnings from a year ago. The consensus estimate is $1.34 per share, down from earnings of $1.81 per share a year ag

LONDON, April 22 (Reuters) - AstraZeneca is to payprivately held Bind Therapeutics as much as $200 million todevelop a cancer medicine using the U.S. biotech company'snanotechnology drug delivery system.

LONDON, April 22 (Reuters) - AstraZeneca is to pay privately held Bind Therapeutics as much as $200 million to develop a cancer medicine using the U.S. biotech company's nanotechnology drug delivery...

LONDON, April 22 (Reuters) - AstraZeneca is to pay privately held Bind Therapeutics as much as $200 million to develop a cancer medicine using the U.S. biotech company's nanotechnology drug delivery system.

LONDON, April 22 (Reuters) - AstraZeneca is to pay privately held Bind Therapeutics as much as $200 million to develop a cancer medicine using the U.S. biotech company's nanotechnology drug delivery system.

AstraZeneca, Telecom Plus, and Barratt Developments are flying.

It's quarterly update time for Standard Life, AstraZeneca, and Unilever.

Local Authority Pension Fund Forum unhappy that new AstraZeneca chief executive will be paid £6.5m golden hello for first three months in post

LONDON, April 15 (Reuters) - A group that represents local pension funds in Britain is recommending that its members vote against the pay package of AstraZeneca's new chief executive.

AstraZeneca PLC

LONDON (Reuters) - Standard & Poor's cut its credit outlook for AstraZeneca to negative from stable on Monday in response to a major strategy update by the drugmaker's new chief executive last month.

* Outlook cut to negative on fears of ongoing sales decline

* New pill fails to impact joint damage measured by X-ray

AstraZeneca (NYSE: AZN) today announced top-line results of OSKIRA-1, a Phase 3 study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA).  OSKIRA-

* Fostamatinib relieves rheumatoid arthritis signs, symptoms

* Fostamatinib relieves rheumatoid arthritis signs, symptoms

* Fostamatinib relieves rheumatoid arthritis signs, symptoms

LONDON, April 5 (Reuters) - AstraZeneca's experimental rheumatoid arthritis pill fostamatinib produced mixed results in a late-stage clinical trial, the company said on Friday.

LONDON, April 5 (Reuters) - AstraZeneca's experimental rheumatoid arthritis pill fostamatinib produced mixed results in a late-stage clinical trial, the company said on Friday.

By Derek Lowe: If you're looking for a sunny, optimistic take on AstraZeneca's (AZN) move to Cambridge in the U.K., the Telegraph has it for you right here. It's a rousing, bullish take on the whole Cambridge scene, but as John Carroll points out at

LONDON, April 3 (Reuters) - AstraZeneca has secured a temporary block on U.S. sales of generic copies of its Pulmicort Repsules asthma drug by Actavis.

LONDON, April 3 (Reuters) - AstraZeneca has secured a temporary block on U.S. sales of generic copies of its Pulmicort Repsules asthma drug by Actavis.

AstraZeneca (NYSE: AZN) today announced that MedImmune, its global biologics research and development unit, has acquired AlphaCore Pharma, an Ann Arbor, Michigan-based biotechnology company focused on the development of ACP-501, a recombinant human l